Carregant...
Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characte...
Guardat en:
| Publicat a: | Vaccines (Basel) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7350268/ https://ncbi.nlm.nih.gov/pubmed/32575350 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8020320 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|